文献检索，用中文搜 PubMed

Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

反义寡核苷酸疗法的开发已经有近 25 年的历史，但在美国食品和药物管理局（FDA）批准的癌症治疗药物中，尚无一种是反义寡核苷酸药物。造成这种情况的部分原因是，人们对如何将这些分子递送到体内的癌细胞中缺乏深入的了解。